StemCell Therapy

Regenerative medicine company Juventas
Therapeutics^[1] is touting
the results from 12-month data of a phase 1 clinical trial of
heart failure patients.

At 12 months, heart failure patients treated with the company’s
stem cell therapy showed “significant” improvements in two key
measures — a six-minute distance-walking test, as well as the
Minnesota Living
with Heart Failure Questionnaire^[2], a
patient self-assessment of how heart failure affects daily
life.

References

1. ^{^} Juventas Therapeutics
   (www.medcitynews.com)
2. ^{^} Minnesota Living with Heart
   Failure Questionnaire (qol.thoracic.org)